Search - tctmd.com

Specialty Menu Navigation

COVID-19
Clinical
Coronary
Structural
Endovascular
Heart Failure
Heart Rhythm
Imaging & Physiology
Policy & Practice

Top User Menu

Main navigation

News
Conferences
Slides
Specialties
Podcasts
Videos
Fellows Forum
CV Team Forum

News (1)

Facet Content type

Facet Podcast

Podcast

(-) Industry News

Facet News Subtype » Taxonomy term » Name

Facet Conference

Conference

Coronary (1)
Diabetes (1)
(-) Stroke (1)

Facet Specialty

2016 (1)

Facet Year

Displaying 1 - 1 of 1

Sort: Relevancy | Date

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

Become a Member

Membership Plans

Sign Up for Our Newsletter

Receive the the latest news, research, and presentations from major meetings right to your inbox.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives. For more information, visit http://www.crf.org.

Main Navigation

News
Conferences
Slides
Videos
Podcasts
Fellows Forum
CV Team Forum
CME

Specialty Menu Navigation

COVID-19
Clinical
Coronary
Structural
Endovascular
Heart Failure
Heart Rhythm
Imaging & Physiology
Policy & Practice

Footer

Advertising & Sponsorships
About TCTMD ®
FAQs
Editorial Policy
Contact Us
About CRF ®

Created by Constructive

Sign In

New at TCTMD? Register today!

Email Address Password

Forgot Password

Forgot Your Password?

Enter the email you used to register to reset your password.

Email Address

Search TCTMD

Content Type

More Type Options

Topic

Year

Conference

Sort

Matching

cme

CME TITLE

First Name

Last Name

Degree

Institution

If other, please specify

AREA OF CLINICAL INTEREST

Address

Address 2 (Optional)

City

State

Zip

Country

Submit a Question for the Panel (Optional)

Sign up for our newsletter

First Name

Last Name

Profession

Organization

Address

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Leave this field blank

Main navigation

News
Conferences
Slides
Specialties
Podcasts
Videos
Fellows Forum
CV Team Forum

Top User Menu

Search TCTMD

Submit an Event

Contact Email

Contact Phone Number

Event Name

Location

Start Date

Start Time

End Date

End Time

Event Description

< >

Become a PREMIUM MEMBER or LOG IN to view exclusive content

This content is available for meeting attendees and/or Platinum Members

REGISTER for free or LOG IN to view this content

Now Playing

Advertisement

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Advertisement